Fred Schaufele, Ph.D., is a co-founder and Director of Scientific Operations and Managing Director at XCellAssay. The technologies being marketed by XCellAssay are modified from the BioAssay measurement studies published by Dr. Schaufele at the University of California, San Francisco where Dr. Schaufele is a Professor in the Center for Reproductive Sciences and in the Department of Obstetrics and Gynecology. At UCSF, Dr. Schaufele studies a variety of endocrine-related syndromes including hormone-related cancers (breast and prostate), diabetes, and disorders of the pituitary system.

HaiGuang Zhang, Ph.D., is a co-founder and Director of Technology at 
XCellAssay. Dr. Zhang had over 10 years of experience at GE Healthcare in the high throughput instrumentation of which the BioAssay technology is based. Dr. Zhang's connections in that area provide XCellAssay with a strong development plan for introduction of the product in high volume markets. Dr. Zhang also has other prior major company and start-up experience. Dr. Zhang's work at GE Healthcare provide XCellAssay with a strong business foundation in the BioAssay area.

Irina Krylova, Ph.D.
, is a co-founder and Director of Environmental Studies at 
XCellAssay. Dr. Krylova has extensive prior experience in academia and biotechnology. This includes outstanding work in the area of nuclear receptors upon which many of the BioAssays are built. As a post-doctoral scholar in Dr. Schaufele's laboratory, Dr. Krylova developed the cellular barcoding technology which XCellAssay is using to measure entire panels of hormones on a fraction of a drop of blood. Dr. Krylova's prior work in industry at Genentech, StemRD and Crystal Biosciences endowed her with valuable experience in drug discovery and development. Dr. Krylova is also a Visiting Professor in the State Key Laboratory of Environmental Chemistry and Ecotoxicology at the Chinese Academy of Sciences in Beijing, China.